Loading…
Shukra Pharmaceuticals (BSE 524632)₹55.87+0.25%Pharmaceuticals
Shukra Pharmaceuticals is compared with the 10 closest in size in Pharmaceuticals (229 companies in the industry). It has a P/E of 73.5 against a peer median of 55.0, and ROCE of 37.0% against a peer median of 12.0%, and latest-quarter sales growth of 380.8% against a peer median of 33.0%. By market cap it is #4 of 11 in this set.
As of · Peer set: 10 closest in size in Pharmaceuticals
| Company | M-cap (₹ Cr) | P/E | ROCE % | ROE % | Debt / equity | Div. yield % | Sales (₹ Cr) | Net profit (₹ Cr) | Qtr sales growth % | Qtr profit growth % | Compare |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Hikal | 2,772 | — | 4.0 | 2.9 | 0.57 | 0.3 | 1,714 | −49 | 6.0 | — | vs BSE 524632 |
| Dishman Carbogen Amcis | 2,616 | 162.2 | 3.0 | 1.6 | 0.46 | 0.0 | 2,927 | 97 | −4.3 | −352.0 | vs BSE 524632 |
| Fredun Pharmaceuticals | 2,507 | 55.0 | 21.1 | 15.7 | 0.80 | 0.0 | 637 | 33 | 89.9 | 85.7 | vs BSE 524632 |
| Shukra Pharmaceuticals | 2,456 | 73.5 | 37.0 | 28.9 | 0.06 | 0.0 | 57 | 22 | 380.8 | 1,190.1 | — |
| Sakar Healthcare | 2,284 | 53.4 | 12.0 | 10.0 | 0.13 | 0.0 | 251 | 30 | 49.9 | 119.8 | vs BSE 524632 |
| Fredun Pharmaceuticals | 2,245 | 49.1 | 21.0 | 15.6 | 0.81 | 0.0 | 636 | 33 | 90.0 | 85.8 | vs BSE 524632 |
| Sai Parenterals | 2,237 | 156.2 | 5.0 | 4.9 | 0.96 | 0.0 | 382 | 14 | 435.6 | 455.2 | vs BSE 524632 |
| Panacea Biotec | 2,206 | — | −2.0 | −2.4 | 0.03 | 0.0 | 641 | −7 | 19.5 | −44.3 | vs BSE 524632 |
| Beta Drugs | 2,089 | 39.0 | 19.0 | 18.9 | 0.11 | 0.0 | 384 | 41 | 33.0 | 58.3 | vs BSE 524632 |
| Indoco Remedies | 2,025 | 63.4 | 1.0 | −9.4 | 1.17 | 0.1 | 1,848 | −99 | 7.2 | — | vs BSE 524632 |
| Windlas Biotech | 2,007 | 30.8 | 16.0 | 12.2 | 0.06 | 0.6 | 906 | 66 | 18.2 | 0.0 | vs BSE 524632 |
| Peer median | 2,245 | 55.0 | 12.0 | 10.0 | 0.46 | 0.0 | 637 | 30 | 33.0 | 85.7 |
Listed companies closest to Shukra Pharmaceuticals in Pharmaceuticals include Hikal, Dishman Carbogen Amcis, Fredun Pharmaceuticals, Sakar Healthcare, Fredun Pharmaceuticals, Sai Parenterals, Panacea Biotec, Beta Drugs.
Hikal, with a market cap of ₹2,772 Cr.
Shukra Pharmaceuticals trades at a P/E of 73.5; the median of its peer set is 55.0. A P/E above or below the median is a description, not a judgement on value.
Shukra Pharmaceuticals' return on capital employed is 37.0%, above the peer median of 12.0%.